Linklaters advises Kartesia on sale of ADL BioPharma
Linklaters has advised Kartesia on the sale of ADL BioPharma to Wacker.
Kartesia is a european provider of capital solutions for small and medium-sized enterprises. The firm provides intelligent and tailored value-added financing solutions to sponsors, management teams and companies in all types of situations, enabling them to accelerate and secure value creation.
On the other hand, ADL BioPharma focuses primarily on two pivots: the development and production of active therapeutic substances (mainly beta-lactam active ingredients), and the development and contract manufacturing of products and intermediates obtained from fermentation processes for third parties in the food, cosmetics and biotech industries.
The Linklaters team advising on this transaction was formed by (pictured from left to right): Carmen Burgos (partner / corporate), Francisco Sainz-Trápaga (partner / banking and finance), Mario García (public law), Ricardo Lecaro and Lucía Herrero (corporate).
